Evidence-aware
Safety focused
Women’s Health Clinic FAQ
Can the O-Shot increase libido?
The O-Shot is not best understood as a libido treatment. It may help some women feel more interested in sex if it improves comfort, lubrication, confidence, or sensitivity, but libido itself is influenced by hormones, sleep, stress, mental health, medication, pain, relationship safety, and overall wellbeing.
Direct answer
The O-Shot is not best understood as a libido treatment. It may help some women feel more interested in sex if it improves comfort, lubrication, confidence, or sensitivity, but libido itself is influenced by hormones, sleep, stress, mental health, medication, pain, relationship safety, and overall wellbeing.
The most useful plan starts with the underlying cause, not the treatment name. Your clinician should review symptoms, medical history, alternatives, expected benefits, limitations and safety.
Educational only. Suitability must be confirmed after consultation. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
At a glance
Clinical summary
O-Shot (PRP)
Clitoral and vaginal Platelet-Rich Plasma injections utilizing growth factors to address sensitivity, scarring, or Lichen Sclerosus.
Evidence Level
Emerging for skin conditions; Anecdotal for orgasmic gain.
G-Shot
Hyaluronic acid filler injected into the anterior vaginal wall.
Evidence Level
Weak; temporary structural augmentation without proven functional translation.
Important safety note
General Risks: Permanent scarring, burns, infection, and chronic tissue damage from energy-based devices or injections.
Suitability
Evidence
Safety
Aftercare
Detailed answer
Detailed answer
The Placebo Factor: The Weinberg meta-analysis indicates a substantial placebo effect in FSD, accounting for 67% of reported improvement. Patients showed a 3. 62 FSFI increase for placebo versus 5. 35 for treatment, meaning only a 1. 73-point increase is attributable to the intervention. Function Restoration vs.
Clinical context
The Placebo Factor: The Weinberg meta-analysis indicates a substantial placebo effect in FSD, accounting for 67% of reported improvement. Patients showed a 3.
Evidence
Symptoms
Alternatives
What it means
The Placebo Factor: The Weinberg meta-analysis indicates a substantial placebo effect in FSD, accounting for 67% of reported improvement. Patients showed a 3.
Why it happens
Function Restoration vs. Creation: Medical interventions are designed to restore function lost to menopause, trauma, or pathology.
Evidence limits
Anatomical Parity: The clitoris and penis share embryological origins, including the corpus cavernosum.
Treatment fit
Hormonal Nuance: Oral estrogens can increase Sex Hormone Binding Globulin (SHBG), which may negate the effects of testosterone therapy.
What this means in practice
Preparation: Use of high-potency numbing agents (30% lidocaine), venous blood draws for PRP, and specific centrifuge processing to isolate growth factors. Provider Standards: Must be performed in CQC-registered facilities by qualified MDs or Specialist Nurses. KOL Status: Leading providers, such as Dr.
PRP (O-Shot): Heightened sensation often reported within 3–7 days (initial fluid volume); endogenous tissue development at 3 weeks; Peak results at 3 months with a typical duration of 1 year.
Patient safety
Why proper assessment matters
Assessment helps separate marketing claims from safe, individualised clinical decision-making.
It checks the cause
The Placebo Factor: The Weinberg meta-analysis indicates a substantial placebo effect in FSD, accounting for 67% of reported improvement. Patients showed a 3.
It protects safety
General Risks: Permanent scarring, burns, infection, and chronic tissue damage from energy-based devices or injections.
It reviews alternatives
Preparation: Use of high-potency numbing agents (30% lidocaine), venous blood draws for PRP, and specific centrifuge processing to isolate growth factors.
It sets expectations
PRP (O-Shot): Heightened sensation often reported within 3–7 days (initial fluid volume); endogenous tissue development at 3 weeks; Peak results at 3 months with a typical duration of.
A clinical decision, not a shortcut
The safest final page should explain what the intervention may do, what it cannot promise, and when another route may be better.
Treatment should be discussed with realistic goals, informed consent, clear aftercare and a plan for review.
Considerations
What to consider
Preparation: Use of high-potency numbing agents (30% lidocaine), venous blood draws for PRP, and specific centrifuge processing to isolate growth factors. Provider Standards: Must be performed in CQC-registered facilities by qualified MDs or Specialist Nurses. KOL Status: Leading providers, such as Dr.
Consultation priorities
Phase 1: First-Line Therapies: Optimization of lifestyle, pelvic floor exercises (PFMT), and hyaluronic acid-based moisturisers.
Consent
Aftercare
Follow-up
Before treatment
Phase 1: First-Line Therapies: Optimization of lifestyle, pelvic floor exercises (PFMT), and hyaluronic acid-based moisturisers.
During care
Phase 2: Medical Standard Care: Topical oestrogen (the gold standard for atrophy) and systemic HRT.
Aftercare
Phase 3: Specialist Referral: Pelvic health physiotherapy and psychosexual therapy to address autonomic tone and psychological factors.
When to reassess
Phase 4: Experimental/Procedural: Consideration of branded/regenerative procedures only after Phases 1–3 fail and a thorough biopsychosocial assessment is complete.
Practical expectations
PRP (O-Shot): Heightened sensation often reported within 3–7 days (initial fluid volume); endogenous tissue development at 3 weeks; Peak results at 3 months with a typical duration of.
Provider Standards: Must be performed in CQC-registered facilities by qualified MDs or Specialist Nurses.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: The O-Shot is a libido booster.
Reality: suitability depends on the symptom pattern, medical history, contraindications, alternatives and individual goals.
Myth: Low libido always means low hormones.
Reality: results vary, evidence may be developing, and non-response should prompt reassessment.
Myth: If sex drive is low, genital PRP should be the.
Reality: injections, devices and intimate procedures can still carry risks and need proper consent and aftercare.
Evidence and advertising
Function Restoration vs. Creation: Medical interventions are designed to restore function lost to menopause, trauma, or pathology.
Alternatives
Preparation: Use of high-potency numbing agents (30% lidocaine), venous blood draws for PRP, and specific centrifuge processing to isolate growth factors.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
General Risks: Permanent scarring, burns, infection, and chronic tissue damage from energy-based devices or injections.
Are alternatives clear?
Preparation: Use of high-potency numbing agents (30% lidocaine), venous blood draws for PRP, and specific centrifuge processing to isolate growth factors.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
General Risks: Permanent scarring, burns, infection, and chronic tissue damage from energy-based devices or injections.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Severe or worsening pain
General Risks: Permanent scarring, burns, infection, and chronic tissue damage from energy-based devices or injections.
Bleeding or discharge
Hormonal Contraindications: Pregnancy, breastfeeding, active liver disease, or a history of hormone-sensitive breast cancer.
Infection signs
Specific BoNT Side Effects: Temporary hyper-sexuality (arousal interrupting daily activities) and a potential decrease in sexual function during the first week post-injection.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
More clinical detail
Benchmark positioning
- The page should win by being the most honest libido answer in a search set that often blends libido with arousal and orgasm.
Clinical reality
- The Placebo Factor: The Weinberg meta-analysis indicates a substantial placebo effect in FSD, accounting for 67% of reported improvement. Patients showed a 3. 62 FSFI increase for placebo versus 5.
- Function Restoration vs. Creation: Medical interventions are designed to restore function lost to menopause, trauma, or pathology. They are ineffective for Primary Anorgasmia, which is typically neurological or psychological rather than structural.
- Anatomical Parity: The clitoris and penis share embryological origins, including the corpus cavernosum. Branded procedures aim to treat the female genitalia as an active system rather than a passive receptacle.
- Hormonal Nuance: Oral estrogens can increase Sex Hormone Binding Globulin (SHBG), which may negate the effects of testosterone therapy. Switching to transdermal estrogen can often restore the "free" testosterone required for clinical response.
Timeline and expectations
- PRP (O-Shot): Heightened sensation often reported within 3–7 days (initial fluid volume); endogenous tissue development at 3 weeks; Peak results at 3 months with a typical duration of 1 year.
- Clitoral BoNT: Clinical results are measured at 4–12 weeks; data indicate patients frequently request retreatment at approximately 6 months.
- Testosterone: A trial period of 3–6 months is mandatory to evaluate efficacy; annual re-evaluation is a regulatory requirement.
- Standard Consultations: Procedural sessions require approximately 30 minutes; hormone reviews occur at 2–3 month intervals.
Practical logistics
- Preparation: Use of high-potency numbing agents (30% lidocaine), venous blood draws for PRP, and specific centrifuge processing to isolate growth factors.
- Provider Standards: Must be performed in CQC-registered facilities by qualified MDs or Specialist Nurses.
- KOL Status: Leading providers, such as Dr. Farzana Khan, serve as Key Opinion Leaders (KOLs) and Trainers for global brands including Neauvia, Asclepion Laser, and RegenLab.
- Cost Range: These are private-pay procedures ranging from $1,200 to $2,500 / £1,200+ per session.
Research sources
- Runels, C. & Runnels, A. (2024): Pilot study on clitoral BoNT/PRP; noted a Cohen’s d of 2.31 for the combined therapy, indicating a robust treatment effect.
- Weinberger, J. M. et al. (2018): Meta-analysis of 3,959 women detailing the high placebo response in FSD trials.
- BMS Management of the Menopause (2026/7th Ed): Essential guidance on intracrinological metabolism and the role of androgens (In Press).
- FDA Safety Communication (2018): Warning against the use of energy-based devices for sexual enhancement due to lack of evidence.
Regulatory resources
Authoritative resources
These resources support assessment-led, evidence-aware patient information.
NICE guidance on vaginal laser for urogenital atrophy
NICE is a UK authority for interventional procedure governance and supports cautious language about evidence, consent and audit.
FDA safety communication on vaginal rejuvenation devices
This safety communication is a useful regulatory reference for avoiding over-claiming around sexual enhancement procedures.
RCOG patient information on menopause symptom treatment
RCOG patient information supports assessment-led discussion of vaginal dryness, discomfort and hormone-related symptoms.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes and aftercare would look like.
▶ View Full Research Bibliography (10 Sources)
Educational only. This document is for educational purposes only and is not a substitute for professional medical advice. Suitability for any procedure must be determined by a qualified clinician following a full assessment. Results vary significantly and these procedures are not a "cure." In a medical emergency, contact NHS 111 or 999. Results vary. Not a cure.
